阴茎球剂量与放疗后18个月勃起功能障碍无关:一项随机试验的二次分析
该随机试验二次分析纳入257例中高危前列腺癌患者,比较宽或紧计划靶区边缘联合内分泌治疗与根治性放疗后18个月性功能,228例可评估患者中2D每周IGRT组与3D每日IGRT组主要结局平均评分分别为7.44与7.39(p=0.93),阴茎球平均剂量在两组间差异较大(59.8 Gy vs 35.1 Gy),但校正后阴茎球平均剂量对主要结局无影响。
要点
- 2D每周IGRT组与3D每日IGRT组主要结局平均评分分别为7.44与7.39(p=0.93)。
- 阴茎球平均剂量2D每周IGRT组59.8 Gy vs 3D每日IGRT组35.1 Gy。
- 校正研究站点、风险组和年龄后,阴茎球平均剂量对主要结局无影响。
核心结论
- 在该研究人群中,IGRT方案或阴茎球剂量对放疗后18个月勃起功能障碍无影响。
- 低效价率可部分归因于高危患者长期使用抗雄激素。
- 需要更长期随访以确认RIC研究的结果。
研究设计与样本
- RIC随机研究二次分析,纳入257例中高危前列腺癌患者。
- 所有患者接受6个月全雄激素阻断,始于随机化前3个月;高危患者额外口服比卡鲁胺2.5年。
- 患者随机接受78 Gy/39次,采用每周离线正交门静脉成像或每日在线锥形束CT图像引导放疗。
- 放疗开始后18个月使用Umeå Fransson Widmark 1994问卷评估性功能,主要结局为勃起能力11点数字评分量表(0=无,10=非常)。
- 分析阴茎球放疗剂量与勃起功能的关系。
主要发现
- 250例可评估患者中228例(平均年龄71.8岁)返回问卷。
- 主要结局问题221例应答者中,2D每周IGRT组与3D每日IGRT组平均评分分别为7.44与7.39(p=0.93)。
- 四个额外性功能问题(量表0-10)平均评分>6.5,研究组间无差异。
- 阴茎球平均剂量2D每周IGRT组59.8 Gy vs 3D每日IGRT组35.1 Gy。
- 校正研究站点、风险组和年龄后,阴茎球平均剂量对主要结局无影响;额外校正18个月血清睾酮水平后,阴茎球平均剂量效应仍不显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更长期随访以确认RIC研究的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Erectile dysfunction is a common side effect of prostate cancer (PC) therapy. In this randomized study (The RIC-study) we used patient reported outcomes to evaluate sexual function 18 months after combined endocrine therapy and radical radiotherapy (RT) given with either wide or tight planning target volume (PTV) margins. We also analyzed the impact of radiation dose to penile bulb on sexual function. METHODS: The RIC-study included 257 men with intermediate and high-risk PC. All patients received 6 months of total androgen blockage started 3 months prior to randomization. In high-risk patients, an oral anti-androgen (Bicalutamide) was administered for an additional 2.5 years. Patients were randomized to receive 78 Gy in 39 fractions guided either by weekly offline orthogonal portal imaging or by daily online cone beam computed tomography image-guided RT. Sexual function was evaluated at 18 months after start of RT using the Questionnaire Umeå Fransson Widmark 1994. Ability to have an erection was assessed on an 11-point scale numerical rating scale (0 = no and 10 = very much) as the primary outcome. In addition, the association between penile bulb (PB) radiation dose and erectile function was analyzed. FINDINGS: Of 250 evaluable patients, 228 (mean age 71.8 years) returned the questionnaires. The patients reported a high degree of sexual related problems with mean scores to the primary outcome question (221 respondents) of 7.44 and 7.39 in the 2D weekly IGRT-arm and 3D daily IGRT-arm (p = 0.93) respectively. For four additional questions (scale 0-10) regarding sexual function resulted in mean scores >6.5 with no difference between study arms. The mean dose to PB was substantially larger in the 2D weekly IGRT-arm vs the 3D daily IGRT-arm (mean 59.8 Gy vs mean 35.1 Gy).We found no effect of mean PB-dose on the primary outcome adjusted for study-site, risk-group and age. When adjusting for serum-testosterone level at 18 months in addition, the effect of mean PB-dose remained insignificant. INTERPRETATION: IGRT protocol or PB dose had no effect on ED 18 months after RT in this study population. The low potency rates can partly be explained by the prolonged use of anti-androgen in high risk patients. Longer follow-up is needed to confirm the results from the RIC-study.
引用
- Tøndel H, Lund JÅ, Lydersen S, et al. Dose to penile bulb is not associated with erectile dysfunction 18 months post radiotherapy: A secondary analysis of a randomized trial. Clin Transl Radiat Oncol. 2018. PMID: 30364704. doi:10.1016/j.ctro.2018.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。